Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574025 | 0.98 | MEN1 (0.57) | TSHRMEN1KMT2AKDM4EGAA | |
| SCHEMBL28198370 | 0.90 | — | — | |
| SCHEMBL14654943 | 0.81 | MAPT (0.45) | TSHRMEN1KMT2AKDM4EPOLB | |
| SCHEMBL4704528 | 0.81 | HRH3 (0.44) | TSHRMEN1KMT2AKDM4EPOLB | |
| SCHEMBL29587148 | 0.80 | MEN1 (0.44) | TSHRMEN1KMT2AKDM4EPOLB | |
| SCHEMBL14652209 | 0.78 | GRM4 (0.43) | TSHRMEN1KMT2AKDM4EEPHX2 | |
| SCHEMBL13326607 | 0.77 | CHRM2 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL13326604 | 0.77 | CHRM2 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL974801 | 0.77 | CHRM2 (0.44) | TSHRMEN1KMT2A | |
| SCHEMBL2402987 | 0.76 | KDM4E (0.51) | TSHRMEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356090-B | Thiazole derivative of a kind of glaucocalyxin A and its preparation method and application | XINXIANG MEDICAL COLLEGE (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-104356090-A | Glaucocalyxin A thiazole derivative, preparation method and application thereof | UNIV XINXIANG MEDICAL | 2015-02-18 | — | — | CN | disclosed |
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1610776-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1515721-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2006-07-26 | — | — | EP | disclosed |
| CN-1791402-A | Ophthalmic compositions for treating ocular hypertension | MERCK & CO INC (US) | 2006-06-21 | — | — | CN | disclosed |
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | EVOTEC OAI (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1610776-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co. Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050256117-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2005-11-17 | — | — | US | disclosed |
| EP-1515721-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004087051-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003105847-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | KCNN1, KCNN3, KCNN2 | TSHR 3877/4885MEN1 1259/4885KMT2A 2607/4885 |
| US-20050256117-A1 | Ophthalmic compositions for treating ocular hypertension | KCNN1, KCNN3, KCNN2 | TSHR 3877/4885MEN1 1259/4885KMT2A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.